Levetiracetam-induced diffuse interstitial lung disease

Scott D. Newsome, Lanny Y. Xue, Timothy Jennings, Glenn Y. Castaneda

Research output: Contribution to journalArticlepeer-review

Abstract

The authors report the first case of levetiracetam-induced diffuse interstitial lung disease. The patient is a 9-year-old girl who was admitted to the pediatric intensive care unit for aspiration pneumonia. She has a history of epilepsy, cerebral palsy, mental retardation, asthma, and repeated hospitalizations for presumed aspiration pneumonia, which resolved with conventional medical treatment. She has been on low-dose levetiracetam for her epilepsy over the past 2 years, and the dosage was increased just prior to this admission. However, this time, with conventional treatment, the patient's aspiration pneumonia did not improve, which led to a lung biopsy. The biopsy demonstrated a diffuse interstitial process of relatively recent onset, with features consistent with diffuse lung disease. Levetiracetam was implicated in the pathogenesis of the interstitial pneumonitis. The patient improved clinically after the discontinuation of levetiracetam and with the treatment of steroids.

Original languageEnglish (US)
Pages (from-to)628-630
Number of pages3
JournalJournal of child neurology
Volume22
Issue number5
DOIs
StatePublished - May 1 2007
Externally publishedYes

Keywords

  • Antiepileptic drug
  • Diffuse lung disease
  • Interstitial lung disease
  • Levetiracetam
  • Pneumonia
  • Pneumonitis

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Clinical Neurology

Fingerprint Dive into the research topics of 'Levetiracetam-induced diffuse interstitial lung disease'. Together they form a unique fingerprint.

Cite this